A 4 Week Randomized, Placebo-Controlled, Parallel Group, Double-Blind Pilot Study to Assess the Safety and Efficacy of Etoricoxib 90 mg Versus Placebo in the Treatment of Cancer Pain
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Bone Neoplasms
Both
Bone Neoplasms
Trial Information
A 4 Week Randomized, Placebo-Controlled, Parallel Group, Double-Blind Pilot Study to Assess the Safety and Efficacy of Etoricoxib 90 mg Versus Placebo in the Treatment of Cancer Pain
Inclusion Criteria:
- Patients are required to have a diagnosis of breast or prostate cancer with bone
involvement and moderate to severe pain that requires opioid treatment.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Outcome Measure:
Analgesic efficacy over a 4 week treatment period; Safety and tolerability.
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Merck
Authority:
United States: Food and Drug Administration
Study ID:
2004_090
NCT ID:
NCT00095017
Start Date:
November 2004
Completion Date:
Related Keywords:
- Bone Neoplasms
- Arcoxia
- Bone Neoplasms
- Neoplasms
Name | Location |
|---|
